Edition:
India

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

10.45USD
23 Feb 2018
Change (% chg)

$0.48 (+4.81%)
Prev Close
$9.97
Open
$9.98
Day's High
$10.50
Day's Low
$9.90
Volume
39,913
Avg. Vol
102,525
52-wk High
$24.35
52-wk Low
$6.31

Select another date:

Wed, Jan 31 2018

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

BRIEF-Syros Prices Public Offering Of 4.19 Mln Common Shares At $9.55/Share

* SYROS ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Syros Announces Proposed Offering Of Common Stock

* SYROS PHARMACEUTICALS INC - ‍OFFERING TO SELL $40.0 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING​ Source text for Eikon: Further company coverage:

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing

* Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing Source text: [http://bit.ly/2hAgfq3] Further company coverage:

BRIEF-Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​

* Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​ Source text for Eikon: Further company coverage:

Select another date: